Abstract 2359
Background
The role of hormonal therapy in the treatment of advanced ovarian cancer (OC) has not been determined yet. Recently the hormone maintenance therapy (HMT) has been actively discussed.
Methods
70 patients (pts) with serous and endometrioid OC stage Ic-IV after 1st line chemotherapy (CT) with paclitaxel/platinum agents and complete (CR) or partial response (PR) were enrolled in phase II study. Pts received HMT with letrozole 2,5 mg per day for 5 years or until disease progression. 71 pts with the same criteria who observed after 1st line CT was taken as retrospective control group. The groups were comparable at baseline including BRCA1/2 status. Paraffin-embedded material (N = 141) after cytoreductive surgery was assessed for presence of estrogen/progesterone receptors (ER/PR) (IGH) and Ki67 in both groups.
Results
Median progression-free survival (PFS) and overall survival (OS) after letrozole maintenance were 18.7 and 51.2 months respectively. In retrospective analysis PFS was significantly longer in letrozole group than in observational group (18.7 and 16.9 months, p = 0.05; HR 0.68, 95%CI 0.44-0.98). There was no any significant difference in overall survival in HMT and observational groups. In the observational group 26 (36,6%) pts received hormone therapy for disease progression later. The expression of ER, PR and Ki67 didn’t have any prognostic and predictive role. Multivariate Cox regression analysis for PFS showed that administration of HMT, stage and response after CT associated with significantly longer PFS. Based on subgroup analysis only pts with stage III-IV with CR after 1st line had significantly longer PFS than pts who underwent observation: 20.9 vs 17.7 months (p = 0.05; HR 0.56, 95%CI 0.32-0.99).
Conclusions
HMT with letrozole could be effective in pts with advanced serous and endometriod OC stage III-IV with CR after 1st line CT regardless of tumour grade. Further randomized studies of HMT are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4842 - The analysis of genomic signatures of head and body/tail of pancreatic cancer in Chinese patients
Presenter: Qi Ling
Session: Poster Display session 2
Resources:
Abstract
4988 - MGMT methylation in metastatic pancreatic cancer (mPAC): a single center experience
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5035 - Advantage of three-dimensional image analysis of pancreatic cancer using computed tomography
Presenter: Seung Bae Yoon
Session: Poster Display session 2
Resources:
Abstract
1465 - Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer.
Presenter: Susumu Hijioka
Session: Poster Display session 2
Resources:
Abstract
1982 - Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trial
Presenter: Mairead McNamara
Session: Poster Display session 2
Resources:
Abstract
2244 - FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: a propensity score analysis
Presenter: Angélique Vienot
Session: Poster Display session 2
Resources:
Abstract
4557 - Cellfree tumor-DNA (cfDNA) as a very early predictor of therapeutic outcome in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Sabine Payr
Session: Poster Display session 2
Resources:
Abstract
4406 - Comprehensive genomic profiling (CGP) of gall bladder adenocarcinoma (GBAC) in patients from distinct ancestral populations
Presenter: Milind Javle
Session: Poster Display session 2
Resources:
Abstract
4283 - Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in Heavily Pre-Treated PDAC Patients.
Presenter: Allyson Ocean
Session: Poster Display session 2
Resources:
Abstract
2078 - Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial
Presenter: Antoine Hollebecque
Session: Poster Display session 2
Resources:
Abstract